November 11, 2011

CLINICAL HOLD REMOVED FOR HELIX BIOPHARMA CORP.’S TOPICAL INTERFERON ALPHA-2B PHASE II/III EFFICACY TRIAL IND APPLICATION (PDF)

AURORA, Ontario, November 11, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical
company developing drug candidates for the prevention and treatment of cancer, today announced that the “clinical hold” on its investigational new drug (“IND”) application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the United States Food and Drug Administration (“FDA”). The FDA completed its review of Helix’s “clinical hold” complete response submission, which Helix filed as announced in its news release of October 12, 2011, and granted Helix approval to perform the planned clinical trial.